Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs
Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases.
- Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases.
- In contrast to legacy cell therapy design, the company uses a combinatorial approach to build and screen cell therapy components that work in concert with one another to yield novel cell behaviors.
- Jason Kelly, CEO and co-founder of Ginkgo Bioworks: "Modulus Therapeutics has built an array of incredible cell therapy assets that we are excited to add into the significant cell therapy capabilities Ginkgo has developed to date.
- Ginkgo expects Modulus' cell therapy assets to help Ginkgo continue to strengthen its CAR-T research & development offerings.